NovaBay Pharma (NYSE:NBY) issued its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by $0.18. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $3.02 million.

NovaBay Pharma (NYSE:NBY) opened at 5.00 on Friday. The company’s 50-day moving average is $4.09 and its 200 day moving average is $3.11. The stock’s market capitalization is $56.26 million. NovaBay Pharma has a one year low of $1.75 and a one year high of $5.29.

Separately, Maxim Group reissued a “hold” rating on shares of NovaBay Pharma in a report on Thursday, October 6th.

NovaBay Pharma Company Profile

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

5 Day Chart for NYSE:NBY

Receive News & Stock Ratings for NovaBay Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharma and related stocks with our FREE daily email newsletter.